Infection & chemotherapy最新文献

{"title":"Weight Gain and Lipid Profile Changes in Koreans with Human Immunodeficiency Virus undergoing Integrase Strand Transfer Inhibitor-Based Regimens.","authors":"Jin Kim,&nbsp;Hyun-Ju Nam,&nbsp;Yu-Jin Jung,&nbsp;Hye-Jung Lee,&nbsp;Seong-Eun Kim,&nbsp;Seung-Ji Kang,&nbsp;Kyung-Hwa Park,&nbsp;Hyun-Ha Chang,&nbsp;Shin-Woo Kim,&nbsp;Eun-Kyung Chung,&nbsp;Uh Jin Kim,&nbsp;Sook In Jung","doi":"10.3947/ic.2022.0063","DOIUrl":"https://doi.org/10.3947/ic.2022.0063","url":null,"abstract":"<p><strong>Background: </strong>This study explored the relationship between integrase strand transfer inhibitor (INSTI)-based anti-retroviral agents and weight gain over time, and the risk factors for weight gain in Korean people living with human immunodeficiency virus (PLWH).</p><p><strong>Materials and methods: </strong>The study was conducted retrospectively in PLWHs 18 years of age or older who took one of three INSTI-based single-tablet regimens (STRs) (tenofovir disoproxil fumarate/emtricitabine/elvitegravir/cobicistat [TDF/F/EVG/c], tenofovir alafenamide/emtricitabine/elvitegravir/cobicistat [TAF/F/EVG/c], and abacavir/lamivudine/dolutegravir [ABC/3TC/DTG]) for more than 2 years at three university-affiliated hospitals in South Korea from May 2014 to December 2020. Analysis was performed in the treatment-naïve and treatment-experienced groups, respectively.</p><p><strong>Results: </strong>Individual INSTI-based STRs were associated with weight gain at the 24-month follow up in both treatment-naïve (n = 179) and treatment-experienced (n = 290) groups. Body mass index (BMI) categories changed over time for TAF/F/EVG/c and ABC/3TC/DTG, with significant increases in the rates of overweight and obesity in treatment-naïve patients, whereas there was no change for TDF/F/EVG/c. TAF/F/EVG/c significantly increased total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and triglyceride (TG) compared to other regimens over 24 months. In the treatment-naïve group, a baseline CD4⁺ T cell count <100 cells/mm³, human immunodeficiency virus (HIV) viral load (VL) ≥100,000 copies/mL, no physical exercise, and TAF/F/EVG/c (<i>vs.</i> TDF/F/EVF/c) were risk factors for ≥10% weight gain. In the treatment-experienced group, age <45 years, BMI <25 kg/m², and no physical exercise were risk factors for ≥5% weight gain.</p><p><strong>Conclusion: </strong>INSTI-based STR continued to increase body weight at the 24-month follow up in treated and untreated Korean PLWH. Exercise, together with demographic-, HIV-, and anti-retroviral therapy-related factors, influenced weight gain. Therefore, when prescribing an INSTI-based STR, weight gain and metabolic changes should be closely monitored in PLWH with these risk factors.</p>","PeriodicalId":520645,"journal":{"name":"Infection & chemotherapy","volume":" ","pages":"419-432"},"PeriodicalIF":4.2,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f3/2f/ic-54-419.PMC9533166.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40667100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regdanvimab Treatment of COVID-19.","authors":"Rujittika Mungmunpuntipantip,&nbsp;Viroj Wiwanitkit","doi":"10.3947/ic.2022.0039","DOIUrl":"https://doi.org/10.3947/ic.2022.0039","url":null,"abstract":"We would like to correspond and share ideas on the publication “Real world experience with regdanvimab treatment of mild-to-moderate coronavirus disease-19 in a COVID-19 designated hospital of Korea [1].” In conclusion, our real-world investigation reveals that regdanvimab treatment of mild-to-moderate COVID-19 considerably slowed disease development; however, the benefit seemed to wane during the Delta variant-dominant wave, according to Hong et al. To investigate the effects of regdanvimab in the period of Omicron dominance and large numbers of vaccinated persons, a large-scale prospective investigation or randomized clinical trial is required [1]. We agree that there might be clinical role of regdanvimab in COVID-19 therapy. In terms of mechanism, it prevents viral spike proteins from interacting with angiotensin-converting enzyme 2 (ACE2), which permits the virus to enter the cell. The current report tried based to control the confounding factors due to demographic background and the concurrent medical problem. It is expected that there should be a controlling of confounding factor from additional alternative therapy for management of infection in each COVID-19 case. Further issue that should be discussed is the impact of genetic polymorphism. Pathophysiologically, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disrupts the ACE/ACE2 balance and activates the reninangiotensin-aldosterone system (RAAS), leading to COVID-19 development, particularly in individuals with comorbidities such hypertension, diabetes, and cardiovascular disease [2]. As a result, ACE2 expression could have contradictory consequences, boosting SARS-CoV-2 pathogenicity while also reducing viral infection [2]. Severity of the infection is reported for association with genetic polymorphism of ACE2 [3]. Therefore, the impact of ACE2 genetic polymorphism might exist and this is an interesting issue for further study in assessment efficacy of the new drug, regdanvimab.","PeriodicalId":520645,"journal":{"name":"Infection & chemotherapy","volume":" ","pages":"547-548"},"PeriodicalIF":4.2,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/94/1b/ic-54-547.PMC9533170.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40667107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of Adverse Outcomes among Women in the Third Trimester of Pregnancy with Coronavirus Disease 2019.","authors":"Hyun Mi Kim,&nbsp;Ki Tae Kwon,&nbsp;Hyun-Hwa Cha,&nbsp;Won Joon Seong,&nbsp;Mi Ju Kim","doi":"10.3947/ic.2022.0065","DOIUrl":"https://doi.org/10.3947/ic.2022.0065","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to compare the clinical and laboratory characteristics of two groups of women (favorable and adverse outcome groups) in the third trimester of pregnancy with coronavirus disease 2019 (COVID-19) and to investigate the predictors of specific adverse outcomes.</p><p><strong>Materials and methods: </strong>We retrospectively reviewed the medical records of patients hospitalized with COVID-19 between November 2020 and October 2021 at Kyungpook National University Chilgok Hospital. Adverse outcomes were clinically defined using the Novel Coronavirus Pneumonia Emergency Response Epidemiology Team criteria. The group without adverse outcomes was defined as the \"favorable outcome\" group and the rest as the \"adverse outcome\" group. We compared the clinical characteristics between the two groups and examined the correlation between their laboratory results and adverse outcomes.</p><p><strong>Results: </strong>Of the 70 pregnant women included, 37 were in their third trimester. No significant differences in clinical characteristics, except the length of hospitalization, were noted between the groups. In laboratory tests conducted immediately after hospitalization, C-reactive protein (CRP) (1.0 [0.3 - 1.4] <i>vs.</i> 2.3 [1.3 - 3.6], <i>P</i> = 0.001) and ferritin (25.0 [14.5 - 34.5] <i>vs.</i> 53.1 [36.0 - 98.0], <i>P</i> <0.03) levels were significantly different between the groups. Logistic regression analysis revealed that CRP (odds ratio [OR]: 2.26; 95% confidence interval [CI]: 1.09 - 5.51, <i>P</i> = 0.040) and ferritin (OR: 1.06; 95% CI: 1.01 - 1.15, <i>P</i> = 0.047) levels were predictors of adverse outcomes.</p><p><strong>Conclusion: </strong>CRP and ferritin levels are associated with poor prognosis and can predict adverse outcomes in women with COVID-19 in the third trimester of pregnancy.</p>","PeriodicalId":520645,"journal":{"name":"Infection & chemotherapy","volume":" ","pages":"493-503"},"PeriodicalIF":4.2,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/91/1f/ic-54-493.PMC9533151.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33487970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantitative Evaluation of the Economic Impact of Antimicrobial Resistance on the Treatment of Community-Acquired Acute Pyelonephritis in Korea.","authors":"Taul Cheong,&nbsp;Jungmo Ahn,&nbsp;Yun Seop Kim,&nbsp;Hyunjoo Pai,&nbsp;Bongyoung Kim","doi":"10.3947/ic.2022.0057","DOIUrl":"https://doi.org/10.3947/ic.2022.0057","url":null,"abstract":"<p><strong>Background: </strong>The proportion of antimicrobial-resistant <i>Enterobacteriales</i> as a causative pathogen of community-acquired acute pyelonephritis (APN) has been increasing. The aim of this study was to quantitatively evaluate the impact of antimicrobial resistance on medical costs and length of hospital stay for the treatment of APN.</p><p><strong>Materials and methods: </strong>A single-center retrospective cohort study was conducted between January 2018 and December 2019. All hospitalized patients aged ≥19 years who were diagnosed with community-acquired APN were recruited, and those diagnosed with <i>Enterobacteriales</i> as a causative pathogen were included. Log-linear regression analysis was performed to determine the risk factors for medical costs and length of hospital stay.</p><p><strong>Results: </strong>A total of 241 patients participated in this study. Of these, 75 (31.1%) and 87 (36.1%) had extended-spectrum beta-lactamase (ESBL)-producing pathogens and ciprofloxacin-resistant pathogens as the causative pathogen, respectively. Based on the log-linear regression model, ESBL-producing <i>Enterobacteriales</i> is a causative pathogen that is, on average, 27.0%, or United States Dollar (USD) 1,211 (<i>P</i> = 0.026) more expensive than non-ESBL-producing <i>Enterobacteriales</i>. A patient who is a year older would incur USD 23 (<i>P</i> = 0.040) more, those having any structural problems in the urinary tract would incur USD 1,231 (<i>P</i> = 0.015) more, and those with a unit increase in the Pitt bacteremia score would incur USD 767 (<i>P</i> <0.001) more, with all other variables constant. Having a case in which ESBL-producing <i>Enterobacteriales</i> is a causative pathogen would explain staying 22.0% longer or 2 more days (<i>P</i> = 0.050) in the hospital than non-ESBL-producing <i>Enterobacteriales</i>. A patient who is 10 years older would, on average, would have to stay for half a day longer (<i>P</i> = 0.045). Any structural problems in the urinary tract explain a longer stay (2.4 days longer; <i>P</i> = 0.032), and moving from 0 to 5 on the Pitt bacteremia score would explain four more days (<i>P</i> = 0.038) in the hospital.</p><p><strong>Conclusion: </strong>Patients with community-acquired APN with ESBL-producing Enterobacteriale as the causative pathogen would incur, on average, 27.0% higher medical costs and 22.0% longer hospitalization days than patients detected with non-ESBL-producing pathogens.</p>","PeriodicalId":520645,"journal":{"name":"Infection & chemotherapy","volume":" ","pages":"456-469"},"PeriodicalIF":4.2,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2a/5d/ic-54-456.PMC9533169.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40335195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bacteremia in Hematopoietic Stem Cell Recipients Receiving Fluoroquinolone Prophylaxis: Incidence, Resistance, and Risk Factors.","authors":"Esma Eryilmaz-Eren,&nbsp;Feyza Izci,&nbsp;Zeynep Ture,&nbsp;Pinar Sagiroglu,&nbsp;Leylagul Kaynar,&nbsp;Aysegul Ulu-Kilic","doi":"10.3947/ic.2022.0005","DOIUrl":"https://doi.org/10.3947/ic.2022.0005","url":null,"abstract":"<p><strong>Background: </strong>Bacteremia is a common complication in hematopoietic stem cell transplant (HSCT) recipients. Prophylactic fluoroquinolone is recommended and used in these individuals. Breakthrough infections can occur with fluoroquinolone-resistant strains. We aimed to identify the incidence, resistance, and risk factors for bacteremia in HSCT recipients receiving fluoroquinolone prophylaxis.</p><p><strong>Materials and methods: </strong>This retrospective study was performed on patients who received fluoroquinolone prophylaxis and underwent autologous and allogeneic HSCT between 2015 and 2019. The incidence of bacteremia, comorbidity, treatment, and invasive procedures was compared in these patients with and without bacteremia.</p><p><strong>Results: </strong>There were 553 patients included in the study, 68 (12.3%) had bacteremia. The incidence of bacteremia is 8.2% of autologous HSCT recipients and 18.4% of allogeneic HSCT recipients. The significant risk factors associated with bacteremia were steroid-using (odds ratio [OR]:13.83, 95% confidence interval [CI]: 2.88 - 66.40), higher Charlson Comorbidity Index (CCI)-mean (OR: 1.57, 95% CI: 1.15 - 2.16), diabetes mellitus (OR: 4.29, 95% CI: 1.11 - 16.48) in autologous HSCT, steroid-using (OR: 6.84, 95% CI: 1.44 - 32.33), longer duration of neutropenia (OR: 1.05, 95% CI: 1.01 - 1.09) using central venous catheter (OR: 7.81, 95% CI: 1.00 - 61.23) in allogeneic HSCT. Seventy-three pathogens were isolated from a total of 68 bacteremia episodes. The most commonly occurring agents were <i>Escherichia coli, Klebsiella pneumoniae</i> and <i>Enterococcus</i> spp. Resistance to fluoroquinolones was 87.2%, 70.0% and 60.0% among these strains, respectively.</p><p><strong>Conclusion: </strong>High CCI, diabetes mellitus, use of steroids and long-term neutropenia and use of central venous catheters were significantly associated with the breakthrough bacteremia in HSCT recipients receiving fluoroquinolone prophylaxis. Fluoroquinolone prophylaxis may reduce the incidence of bacteremia but may select strains resistant to fluoroquinolone.</p>","PeriodicalId":520645,"journal":{"name":"Infection & chemotherapy","volume":" ","pages":"446-455"},"PeriodicalIF":4.2,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/54/b1/ic-54-446.PMC9533163.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40335196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hallucinations in Children with Plague: A Point of View from 400 Years Ago.","authors":"Kun Hwang","doi":"10.3947/ic.2022.0055","DOIUrl":"https://doi.org/10.3947/ic.2022.0055","url":null,"abstract":"https://icjournal.org Fever is one of the symptoms of coronavirus disease 2019 (COVID-19), which is prevalent both in Korea and in other countries throughout the world. Fever is defined as an oral temperature of 37.8°C or higher or a rectal temperature of 38.2°C or higher. There are many causes of fever, including infections such as bacteria and viruses. When the body heat rises, blood vessels dilate to lower the core body temperature, increasing sweat secretion.","PeriodicalId":520645,"journal":{"name":"Infection & chemotherapy","volume":" ","pages":"563-565"},"PeriodicalIF":4.2,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b5/32/ic-54-563.PMC9533171.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40667104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tigecycline for Severe Rickettsioses: Gained Experience Needing a Slight Grain of Salt.","authors":"Lucas S Blanton,&nbsp;Álvaro A Faccini-Martínez","doi":"10.3947/ic.2022.0046","DOIUrl":"https://doi.org/10.3947/ic.2022.0046","url":null,"abstract":"We read with interest the article by Mastroianni and colleagues titled “Does Tigecycline Have a Place in Therapy for Rickettsial Infection of the Central Nervous System [1].” In this report, the authors describe their experience using tigecycline to treat those with neurologic manifestations of spotted fever group (SFG) rickettsiosis in Italy. In their series of 5 patients, they report a favorable response to the use of high dose tigecycline (200 mg loading dose followed by 100 mg administered twice daily). Tigecycline, a relatively unproven antibiotic for clinical rickettsioses, has in vitro activity against several tested rickettsiae [2, 3] and appears effective in an animal model for lethal Rocky Mountain spotted fever (RMSF) [3]. Although doxycycline is the agent of choice, manifestations such as nausea/vomiting or concern for impaired absorption associated with critical illness, may preclude its oral use. Unfortunately, as highlighted by this article, the parenteral formulation is not always available in some regions [1, 3]. Sharing clinical therapeutic experience through publication of observational studies is of importance when controlled trials are not feasible, so the case series by Mastroianni et al. [1] may be very helpful to clinicians faced with severe manifestations of SFG rickettsioses without the availability of intravenous doxycycline.","PeriodicalId":520645,"journal":{"name":"Infection & chemotherapy","volume":" ","pages":"545-546"},"PeriodicalIF":4.2,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/38/48/ic-54-545.PMC9533161.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40667105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Incidence and Risk Factors of Renal Insufficiency among Korean HIV infected Patients: The Korea HIV/AIDS Cohort Study.","authors":"Jun Hyoung Kim,&nbsp;Heeseon Jang,&nbsp;Jung Ho Kim,&nbsp;Joon Young Song,&nbsp;Shin-Woo Kim,&nbsp;Sang Il Kim,&nbsp;Bo Youl Choi,&nbsp;Jun Yong Choi","doi":"10.3947/ic.2022.0101","DOIUrl":"https://doi.org/10.3947/ic.2022.0101","url":null,"abstract":"<p><p>Renal insufficiency is one of the common issues in people living with human immunodeficiency virus (PLHIV). We studied the incidence and risk factors for renal insufficiency in male PLHIV using the Korea HIV/acquired immunodeficiency syndrome (AIDS) Cohort Study. Among the 830 enrolled patients, 32 (3.9%) cases of renal insufficiency occurred over 9576 patient-years of follow-up. The incidence of renal insufficiency in HIV-infected men in this study was 3.3 per 1000 patient-years. Diabetes mellitus, dyslipidemia, tenofovir or non-nucleoside reverse transcriptase inhibitor exposure for >1 year, and AIDS-defining illness were risk factors for renal insufficiency.</p>","PeriodicalId":520645,"journal":{"name":"Infection & chemotherapy","volume":" ","pages":"534-541"},"PeriodicalIF":4.2,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/68/5f/ic-54-534.PMC9533162.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33487973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Characteristics and Pregnancy-Related Outcomes of Pregnant Women Hospitalized with COVID-19 During the Delta Wave: A Single-Center Observational Study.","authors":"Shin Hee Hong,&nbsp;Hye Jin Shi,&nbsp;Suk Young Kim,&nbsp;Yoonseon Park,&nbsp;Joong Sik Eom","doi":"10.3947/ic.2022.0072","DOIUrl":"https://doi.org/10.3947/ic.2022.0072","url":null,"abstract":"<p><strong>Background: </strong>Coronavirus disease 2019 (COVID-19) during pregnancy is associated with increased disease severity and an increased risk of perinatal complications. However, few studies of pregnant women with COVID-19 have been conducted in Korea. The purpose of this study was to describe the clinical course and pregnancy outcomes of pregnant women admitted to our hospital with COVID-19 according to the severity.</p><p><strong>Materials and methods: </strong>This retrospective cohort study included women aged 18 years of age or older who were hospitalized in the Gachon University Gil Medical Center with COVID-19 during pregnancy between July 1, 2021 and January 31, 2022. COVID-19 severity was classified according to the \"Criteria for severity classification by symptoms of COVID-19\" presented by the Korea Disease Control and Prevention Agency. Severe cases were defined as those who required oxygen treatment administered via a high-flow nasal cannula or invasive mechanical ventilation or should be applied extracorporeal membrane oxygenation (ECMO) or continuous renal replacement therapy.</p><p><strong>Results: </strong>A total of 103 pregnant women were hospitalized with COVID-19 during the study period. Their mean age was 33 (± 4.14) years, and 4 (3.9%) had been vaccinated against COVID-19. At the time of diagnosis of COVID-19, 3 (2.9%), 33 (32.0%), and 67 (65.1%) patients were in the first, second, and third trimester, respectively. The most common symptoms were cough (99 patients, 96.1%) and fever (85 patients, 82.5%). There was 1 (1.0%) asymptomatic patient. Forty patients (38.8%) required supplemental oxygen and 19 patients (18.4%) had severe disease. Of the 19 severe cases, 7 were in the 2nd trimester and 12 were in the 3rd trimester. Forty-one (39.8%) patients delivered, including two twin deliveries. Of the 41 cases of delivery, 14 were premature, 4 out of 21 (19.0%) in mild, 4 out of 12 (25.0%) in moderate, and 6 out of 8 (75.0%) in severe. Severe disease was associated with an increased rate of preterm birth (<i>P</i> = 0.012). Four of the 43 neonates (9.1%) received oxygen treatment.</p><p><strong>Conclusion: </strong>Pregnant women with COVID-19 had a high rate of severe disease and a high preterm delivery rate, especially among those with severe disease.</p>","PeriodicalId":520645,"journal":{"name":"Infection & chemotherapy","volume":" ","pages":"433-445"},"PeriodicalIF":4.2,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/57/9f/ic-54-433.PMC9533157.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40667101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ten-Year Trends of Hepatitis A Seroprevalence in People Living with HIV in Korea.","authors":"Shinwon Lee,&nbsp;Jeong Eun Lee,&nbsp;Soon Ok Lee,&nbsp;Yong Ki Sim,&nbsp;Sun Hee Lee","doi":"10.3947/ic.2022.0062","DOIUrl":"https://doi.org/10.3947/ic.2022.0062","url":null,"abstract":"<p><p>Epidemiological information on hepatitis A among people living with HIV (PLHIV) in Korea is scarce. This retrospective study was performed at a tertiary care hospital and included 756 PLHIV with anti- hepatitis A virus (HAV) IgG tests. Between 2012 and 2021, the age at anti-HAV IgG seroconversion is gradually delayed, and the proportion of individuals susceptible to HAV infection increased among adult PLHIV in Korea. The independent risk factors for HAV seropositivity were female sex and HBs antigen (Ag) positivity. Therefore, HAV vaccination is highly recommended for young PLHIV, especially for women or HBsAg-positive individuals.</p>","PeriodicalId":520645,"journal":{"name":"Infection & chemotherapy","volume":" ","pages":"529-533"},"PeriodicalIF":4.2,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3b/53/ic-54-529.PMC9533165.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40667103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}